GTx-758

GTx-758 (also known as Capesaris) is an estrogen receptor agonist that is under development by GTx for the treatment of prostate cancer. It is a selective estrogen receptor alpha agonist.

Mechanism of action

GTx-758 works by increasing the levels of sex hormone-binding globulin (SHBG) in the body, which in turn reduces the amount of free, active testosterone available to stimulate the growth of prostate cancer cells. It also directly inhibits the growth of prostate cancer cells by binding to estrogen receptors.

Clinical trials

GTx-758 has been studied in phase II clinical trials for the treatment of advanced prostate cancer. The results of these trials have shown that GTx-758 can significantly reduce testosterone levels in men with prostate cancer, and it has a favorable safety profile.

Side effects

The most common side effects of GTx-758 include hot flashes, gynecomastia, and venous thromboembolism. These side effects are generally mild and manageable.

See also

• List of investigational hormonal agents
• List of investigational antineoplastics

GTx-758 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski